Takeda Hid 'Dangerously Defective' Gout Drug's Risks

Law360 (October 28, 2019, 5:14 PM EDT) -- Takeda Pharmaceuticals USA Inc. failed to warn doctors and patients about the risks of taking its "dangerously defective" prescription drug Uloric to treat gout, a man who claims he suffered a heart attack from taking the drug said in an Illinois federal court suit Monday.

Peter Gust Karidis says in his lawsuit that he suffered a heart attack as a result of using the gout medication in 2016. He claims the company knew of the link between Uloric and "major adverse cardiovascular events," but entered into a scheme to conceal that connection from the public and submitted false reports to the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!